Topical retinoids in acne - An evidence-based overview;Topische retinoide bei akne - Eine evidenzbasierte übersicht

JDDG - Journal of the German Society of Dermatology

Volumn 8, Issue SUPPL. 1, 2010, Pages

  Thielitz, Anja ^a   Abdel Naser, Mohamed B ^b,c   Fluhr, Joachim W ^d   Zouboulis, Christos C ^c   Gollnick, Harald ^a  

^a OTTO VON GUERICKE UNIVERSITY   (Germany)

^b AIN SHAMS UNIVERSITY   (Egypt)

^c Klinik für Dermatologie Venerologie Allergologie und Immunologie   (Germany)

^d Bioskin Berlin   (Germany)

Author keywords

Acne; Evidence based medicine; Safety; Therapy; Topical retinoids

Indexed keywords

ADAPALENE; BENZOYL PEROXIDE; CLINDAMYCIN; CLINDAMYCIN PHOSPHATE; DOXYCYCLINE; ERYTHROMYCIN; GLYCOLIC ACID; ISOTRETINOIN; ISOTREXIN; LYMECYCLINE; MINOCYCLINE; RETINAL; RETINOIC ACID; RETINOID; TAZAROTENE; UNCLASSIFIED DRUG; ZIANA;

ACNE; ANTIINFLAMMATORY ACTIVITY; COMEDO; DRUG ABSORPTION; DRUG EFFICACY; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; MAINTENANCE THERAPY; MONOTHERAPY; PROPIONIBACTERIUM ACNES; REMISSION; REVIEW; TOPICAL TREATMENT;

EID: 77951444720     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2008.06741_suppx.x     Document Type: Review

References (91)

1. Lavker RM, Leyden JJ, Thorne EG. An ultrastructural study of the effects of topical tretinoin on microcomedones. Clin Ther 1992; 14: 773-780. (Pubitemid 23040445)
2. Thielitz A, Helmdach M, Ropke EM, Gollnick H. Lipid analysis of follicular casts from cyanoacrylate strips as a new method for studying therapeutic effects of antiacne agents. Br J Dermatol 2001; 145: 19-27. (Pubitemid 32862781)
3. Thielitz A, Sidou F, Gollnick H. Control of microcomedone formation throughout a maintenance treatment with adapalene gel, 0.1 %. J Eur Acad Dermatol Venereol 2007; 21: 747-753. (Pubitemid 46939044)
4. Gollnick H, Cunliffe W, Berson D, Dreno B, Finlay A, Leyden JJ, Shalita AR, Thiboutot D; Global Alliance to Improve Outcomes in Acne. Management of acne: a report from a Global Alliance to Improve Outcomes in Acne. J Am Acad Dermatol 2003; 49: S1-37.
5. Leyden JJ. A review of the use of combination therapies for the treatment of acne vulgaris. J Am Acad Dermatol 2003; 49: S200-S210.
6. Webster G. Mechanism-based treatment of acne vulgaris: the value of combination therapy. J Drugs Dermatol 2005; 4: 281-288.
7. Sackett D, Strauss S, Richardson W, Rosenberg W, Haynes R. Evidence-based medicine: how to practise and teach EBM. London: Churchill Livingstone, 2001: 169-182.
8. Bikowski JB. Mechanisms of the comedolytic and anti-inflammatory properties of topical retinoids. J Drugs Dermatol 2005; 4: 41-47.
9. Kang S. The mechanism of action of topical retinoids. Cutis 2005; 75:10-13.
10. Pechere M, Pechere JC, Siegenthaler G, Germanier L, Saurat JH. Antibacterial activity of retinaldehyde against Propionibacterium acnes. Dermatology 1999; 199 Suppl 1: 29-31. (Pubitemid 29378242)
11. Jones DA. The potential immunomodulatory effects of topical retinoids. Dermatol Online J 2005; 11: 3.
12. Wolf JE, Jr. Potential anti-inflammatory effects of topical retinoids and retinoid analogues. Adv Ther 2002; 19: 109-118.
13. Krishnan G. Comparison of two concentrations of tretinoin solution in the topical treatment of acne vulgaris. Practitioner 1976; 216: 106-109.
14. Christiansen J, Holm P, Reymann F. The retinoic acid derivative Ro 11-1430 in Acne vulgaris. A controlled multicenter trial against retinoic acid. Dermatologica 1977; 154: 219-227.
15. Webster GF. Safety and efficacy of Tretin-X compared with Retin-A in patients with mild-to-severe acne vulgaris. Skinmed 2006; 5: 114-118.
16. Skov MJ, Quigley JW, Bucks DA. Topical delivery system for tretinoin: research and clinical implications. J Pharm Sci 1997; 86: 1138-1143.
17. Galvin SA, Gilbert R, Baker M, Guibal F, Tuley MR. Comparative tolerance of adapalene 0.1 % gel and six different tretinoin formulations. Br J Dermatol 1998; 139 Suppl 52: 34-40. (Pubitemid 28475282)
18. Quigley JW, Bucks DA. Reduced skin irritation with tretinoin containing polyolprepolymer-2, a new topical tretinoin delivery system: a summary of preclinical and clinical investigations. J Am Acad Dermatol 1998; 38: S5-10.
19. Berger R, Barba A, Fleischer A, Leyden JJ, Lucky A, Pariser D, Rafal E, Thiboutot D, Wilson D, Grossman R, Nighland M. A double-blinded, randomized, vehicle-controlled, multicenter, parallel-group study to assess the safety and efficacy of tretinoin gel microsphere 0.04 % in the treatment of acne vulgaris in adults. Cutis 2007; 80: 152-157.
20. Berger R, Rizer R, Barba A, Wilson D, Stewart D, Grossman R, Nighland M, Weiss J. Tretinoin gel microspheres 0.04 % versus 0.1 % in adolescents and adults with mild to moderate acne vulgaris: a 12-week, multicenter, randomized, double-blind, parallel-group, phase IV trial. Clin Ther 2007; 29: 1086-1097. (Pubitemid 47198892)
21. Lucky AW, Cullen SI, Jarratt MT, Quigley JW Comparative efficacy and safety of two 0.025 % tretinoin gels: results from a multicenter double-blind, parallel study. J Am Acad Dermatol 1998; 38: S17-S23.
22. Lucky AW, Cullen SI, Funicella T, Jarratt MT, Jones T, Reddick ME. Double-blind, vehicle-controlled, multi-center comparison of two 0.025 % tretinoin creams in patients with acne vulgaris. J Am Acad Dermatol 1998; 38: S24-S30.
23. Mills OH, Jr., Kligman AM. Treatment of acne vulgaris with topically applied erythromycin and tretinoin. Acta Derm Venereol 1978; 58: 555-557. (Pubitemid 9125845)
24. Korting HC, Braun-Falco O. Efficacy and tolerability of combined topical treatment of acne vulgaris with tretinoin and erythromycin in general practice. Drugs Exp Clin Res 1989; 15: 447-451. (Pubitemid 20041276)
25. Kreusch J, Bextermoller R. Efficacy and tolerability of a topical erythromycin/ tretinoin combination preparation in acne treatment: post-marketing surveillance study involving over 6500 patients. Curr Med Res Opin 2000; 16: 1-7. (Pubitemid 30107746)
26. Gupta AK Lynde CW, Kunynetz RA, Amin S, Choi K, Goldstein E. A randomized, double-blind, multicenter, parallel group study to compare relative efficacies of the topical gels 3 % erythromycin/5 % benzoyl peroxide and 0.025 % tretinoin/erythromycin 4 % in the treatment of moderate acne vulgaris of the face. J Cutan Med Surg 2003; 7: 31-37. (Pubitemid 36350856)
27. Handojo I. Retinoic acid cream (Airol cream) and benzoyl-peroxide in the treatment of acne vulgaris. Southeast Asian J Trop Med Public Health 1979; 10: 548-551.
28. Nyirady J, Lucas C, Yusuf M, Mignone P, Wisniewski S. The stability of tretinoin in tretinoin gel microsphere 0.1 %. Cutis 2002; 70: 295-298. (Pubitemid 41750803)
29. Shalita AR, Rafal ES, Anderson DN, Yavel R, Landow S, Lee WL. Compared efficacy and safety of tretinoin 0.1 % microsphere gel alone and in combination with benzoyl peroxide 6 % cleanser for the treatment of acne vulgaris. Cutis 2003; 72: 167-172. (Pubitemid 37229749)
30. Zouboulis CC, Derumeaux L, Decroix J, Maciejewska-Udziela B, Cambazard F, Stuhlert A. A multicentre, single-blind, randomized comparison of a fixed clindamycin phosphate/tretinoin gel formulation (Velac) applied once daily and a clindamycin lotion formulation (Dalacin T) applied twice daily in the topical treatment of acne vulgaris. Br J Dermatol 2000; 143: 498-505.
31. Richter JR, Forstrom LR, Kiistala UO, Jung EG. Efficacy of the fixed 1.2 % clindamycin phosphate, 0.025 % tretinoin gel formulation (Velac) and a proprietary 0.025 % tretinoin gel formulation (Aberela) in the topical control of facial acne. J Eur Acad Dermatol Venereol 1998; 11: 227-233.
32. Leyden JJ, Krochmal L, Yaroshinsky A. Two randomized, double-blind, controlled trials of 2219 subjects to compare the combination clindamycin/tretinoin hydrogel with each agent alone and vehicle for the treatment of acne vulgaris. J Am Acad Dermatol 2006; 54: 73-81. (Pubitemid 41832461)
33. Schlessinger J, Menter A, Gold M, Leonardi C, Eichenfield L, Plott RT, Leyden J, Wortzman M; ZIANA Study Group. Clinical safety and efficacy studies of a novel formulation combining 1.2 % clindamycin phosphate and 0.025 % tretinoin for the treatment of acne vulgaris. J Drugs Dermatol 2007; 6: 607-615.
34. Bowman S, Gold M, Nasir A, Vamvakias G. Comparison of clindamycin/benzoyl peroxide, tretinoin plus clindamycin, and the combination of clindamycin/benzoyl peroxide and tretinoin plus clindamycin in the treatment of acne vulgaris: a randomized, blinded study. J Drugs Dermatol 2005; 4: 611-618.
35. Chalker DK, Lesher JL Jr, Smith JG Jr, Klauda HC, Pochi PE, Jacoby WS, Yonkosky DM, Voorhees JJ, Ellis CN, Matsuda-John S, et al. Efficacy of topical isotretinoin 0.05 % gel in acne vulgaris: results of a multicenter, double-blind investigation. J Am Acad Dermatol 1987; 17: 251-254.
36. Dominguez J, Hojyo MT, Celayo JL, Dominguez-Soto L, Teixeira F. Topical isotretinoin vs. topical retinoic acid in the treatment of acne vulgaris. Int J Dermatol 1998; 37: 54-55. (Pubitemid 28201875)
37. Ioannides D, Rigopoulos D, Katsambas A. Topical adapalene gel 0.1 % vs. isotretinoin gel 0.05 % in the treatment of acne vulgaris: a randomized open-label clinical trial. Br J Dermatol 2002; 147: 523-527. (Pubitemid 35015289)
38. Hughes BR, Norris JF, Cunliffe WJ. A double-blind evaluation of topical isotretinoin 0.05 %, benzoyl peroxide gel 5 % and placebo in patients with acne. Clin Exp Dermatol 1992; 17: 165-168.
39. Glass D, Boorman GC, Stables GI, Cunliffe WJ, Goode K. A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05 %) and erythromycin (2 %) with gels containing isotretinoin (0.05 %) or erythromycin (2 %) alone in the topical treatment of acne vulgaris. Dermatology 1999; 199: 242-247.
40. Marazzi P, Boorman GC, Donald AE, Davies HD. Clinical evaluation of Double Strength Isotrexin versus Benzamycin in the topical treatment of mild to moderate acne vulgaris. J Dermatolog Treat 2002; 13: 111-117.
41. Cunliffe WJ, Poncet M, Loesche C, Verschoore M. A comparison of the efficacy and tolerability of adapalene 0.1 % gel versus tretinoin 0.025 % gel in patients with acne vulgaris: a meta-analysis of five randomized trials. Br J Dermatol 1998; 139 Suppl 52: 48-56. (Pubitemid 28475284)
42. Ellis CN, Millikan LE, Smith EB, Chalker DM, Swinyer LJ, Katz IH, Berger RS, Mills OH Jr, Baker M, Verschoore M, Loesche C. Comparison of adapalene 0.1 % solution and tretinoin 0.025 % gel in the topical treatment of acne vulgaris. Br J Dermatol 1998; 139 Suppl 52: 41-47. (Pubitemid 28475283)
43. Thiboutot D, Gold MH, Jarratt MT, Kang S, Kaplan DL, Millikan L, Wolfe J, Loesche C, Baker M. Randomized controlled trial of the tolerability, safety, and efficacy of adapalene gel 0.1 % and tretinoin microsphere gel 0.1 % for the treatment of acne vulgaris. Cutis 2001; 68: 10-19.
44. Pierard-Franchimont C, Henry F, Fraiture AL, Fumal I, Pierard GE. Split-face clinical and bio-instrumental comparison of 0.1 % adapalene and 0.05 % tretinoin in facial acne. Dermatology 1999; 198: 218-222. (Pubitemid 29204622)
45. Cunliffe WJ, Danby FW, Dunlap F, Gold MH, Gratton D, Greenspan A. Randomised, controlled trial of the efficacy and safety of adapalene gel 0.1 % and tretinoin cream 0.05 % in patients with acne vulgaris. Eur J Dermatol 2002; 12: 350-354. (Pubitemid 34713101)
46. Lucky A, Jorizzo JL, Rodriguez D, Jones TM, Stewart DM, Tschen EH, Kanof NB, Miller BH, Wilson DC, Loven KH. Efficacy and tolerance of adapalene cream 0.1 % compared with its cream vehicle for the treatment of acne vulgaris. Cutis 2001; 68: 34-40.
47. Thiboutot D, Pariser DM, Egan N, Flores J, Herndon JH Jr, Kanof NB, Kempers SE, Maddin S, Poulin YP, Wilson DC, Hwa J, Liu Y, Graeber M; Adapalene Study Group. Adapalene gel 0.3 % for the treatment of acne vulgaris: a multicenter, randomized, double-blind, controlled, phase III trial. J Am Acad Dermatol 2006; 54: 242-250. (Pubitemid 43144393)
48. Pariser DM, Thiboutot DM, Clark SD, Jones TM, Liu Y, Graeber M. The efficacy and safety of adapalene gel 0.3 % in the treatment of acne vulgaris: A randomized, multicenter, investigator-blinded, controlled comparison study versus adapalene gel 0.1 % and vehicle. Cutis 2005; 76: 145-151. (Pubitemid 41290901)
49. Wolf JE Jr, Kaplan D, Kraus SJ, Loven KH, Rist T, Swinyer LJ, Baker MD, Liu YS, Czernielewski J. Efficacy and tolerability of combined topical treatment of acne vulgaris with adapalene and clindamycin: a multicenter, randomized, investigator-blinded study. J Am Acad Dermatol 2003; 49: S211-S217. (Pubitemid 37046535)
50. Zhang JZ, Li LF, Tu YT, Zheng J. A successful maintenance approach in inflammatory acne with adapalene gel 0.1 % after an initial treatment in combination with clindamycin topical solution 1 % or after monotherapy with clindamycin topical solution 1 %. J DermatologTreat 2004; 15: 372-378. (Pubitemid 39657848)
51. Thiboutot DM, Weiss J, Bucko A, Eichenfield L, Jones T, Clark S, Liu Y, Graeber M, Kang S; Adapalene-BPO Study Group. Adapalene-benzoyl peroxide, a fixed-dose combination for the treatment of acne vulgaris: Results of a multicenter, randomized double-blind, controlled study. J Am Acad Dermatol. 2007; 57(5): 791-799. (Pubitemid 47553072)
52. Del Rosso JQ. Study results of benzoyl peroxide 5 %/clindamycin 1 % topical gel, adapalene 0.1 % gel, and use in combination for acne vulgaris. J Drugs Dermatol 2007; 6: 616-622.
53. Cunliffe WJ, Meynadier J, Alirezai M, George SA, Coutts I, Roseeuw DI, Hachem JP, Briantais P, Sidou F, Soto P. Is combined oral and topical therapy better than oral therapy alone in patients with moderate to moderately severe acne vulgaris? A comparison of the efficacy and safety of lymecycline plus adapalene gel 0.1 %, versus lymecycline plus gel vehicle. J Am Acad Dermatol 2003; 49: S218-S226. (Pubitemid 37046536)
54. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Arsonnaud S, Kang S. Combination therapy with adapalene gel 0.1 % and doxycycline for severe acne vulgaris: a multicenter, investigator-blind, randomized, controlled study. Skinmed 2005; 4: 138-146.
55. Shalita AR, Chalker DK, Griffith RF, Herbert AA, Hickman JG, Maloney JM, Miller BH, Tschen EH, Chandraratna RA, Gibson JR, Lew-Kaya DA, Lue JC, Sefton J. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis 1999; 63: 349-354.
56. Shalita AR, Berson DS, Thiboutot DM, Leyden JJ, Parizadeh D, Sefton J, Walker PS, Gibson JR; Tazarotene Cream in Acne Clinical Study Investigator Group. Effects of tazarotene 0.1 % cream in the treatment of facial acne vulgaris: pooled results from two multicenter, double-blind, randomized, vehicle-controlled, parallel-group trials. Clin Ther 2004; 26: 1865-1873.
57. Webster GF, Berson D, Stein LF, Fivenson DP, Tanghetti EA, Ling M. Efficacy and tolerability of once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.025 % gel in the treatment of facial acne vulgaris: a randomized trial. Cutis 2001; 67: 4-9.
58. Leyden JJ, Tanghetti EA, Miller B, Ung M, Berson D, Lee J. Once-daily tazarotene 0.1 % gel versus once-daily tretinoin 0.1 % microsponge gel for the treatment of facial acne vulgaris: a double-blind randomized trial. Cutis 2002; 69: 12-19.
59. Webster GF, Guenther L, Poulin YP, Solomon BA, Loven K Lee J. A multicenter, double-blind, randomized comparison study of the efficacy and tolerability of once-daily tazarotene 0.1 % gel and adapalene 0.1 % gel for the treatment of facial acne vulgaris. Cutis 2002; 69: 4-11.
60. Shalita A, Miller B, Menter A, Abramovits W, Loven K, Kakita L. Tazarotene cream versus adapalene cream in the treatment of facial acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. J Drugs Dermatol 2005; 4: 153-158.
61. Leyden J, Lowe N, Kakita L, Draelos Z. Comparison of treatment of acne vu garis with alternate-day applications of tazarotene 0.1 % gel and once-daily a plications of adapalene 0.1 % gel: a randomized trial. Cutis 2001; 67: 10-16.
62. Bershad S, Kranjac Singer G, Parente JE, Tan MH, Sherer DW, Persaud AN, Lebwohl M. Successful treatment of acne vulgaris using a new method: results of a randomized vehicle-controlled trial of short-contact therapy with 0.1 % tazarotene gel. Arch Dermatol 2002; 138: 481-489. (Pubitemid 34292500)
63. Draelos ZD, Tanghetti EA. Optimizing the use of tazarotene for the treatment of facial acne vulgaris through combination therapy. Cutis 2002; 69: 20-29.
64. Tanghetti E, Abramovits W, Solomon B, Loven K, Shalita A. Tazarotene versus tazarotene plus clindamycin/benzoyl peroxide in the treatment of acne vulgaris: a multicenter, double-blind, randomized parallel-group trial. J Drugs Dermatol 2006; 5: 256-261.
65. Fort-Lacoste L, Verscheure Y, Tisne-Versailles J, Navarro R. Comedolytic effect of topical retinaldehyde in the rhino mouse model. Dermatology 1999; 199 Suppl 1: 33-35.
66. Poli F, Ribet V, Lauze C, Adhoute H, Morinet P. Efficacy and safety of 0.1 % retinaldehyde/ 6 % glycolic acid (diacneal) for mild to moderate acne vulgaris. A multicentre, double-blind, randomized, vehicle-controlled trial. Dermatology 2005; 210 Suppl 1: 14-21.
67. Dreno B, Nocera T, Verrière F, Vienne MP, Ségard C, Vitse S, Carré C. Topical retinaldehyde with glycolic acid: study of tolerance and acceptability in association with anti-acne treatments in 1,709 patients. Dermatology 2005; 210 Suppl 1: 22-29.
68. Dreno B, Katsambas A, Pelfini C, Plantier D, Jancovici E, Ribet V, Nocera T, Morinet P, Khammari A. Combined 0.1 % retinaldehyde/ 6 % glycolic acid cream in prophylaxis and treatment of acne scarring. Dermatology 2007; 214: 260-267. (Pubitemid 46457613)
69. Morel P, Vienne MP, Beylot C, Bonérandi JJ, Dréno B, Lehucher-Ceyrac D, Slimani S, Dupuy P. Clinical efficacy and safety of a topical combination of retinaldehyde 0.1 % with erythromycin 4 % in acne vulgaris. Clin Exp Dermatol 1999; 24: 354-357. (Pubitemid 29491202)
70. Fluhr JW Vienne MP, Lauze C, Dupuy P, Gehring W Gloor M. Tolerance profile of retinol, retinaldehyde and retinoic acid under maximized and long-term clinical conditions. Dermatology. 1999; 199 Suppl 1: 57-60.
71. Thiboutot DM, Shalita AR, Yamauchi PS, Dawson C, Kerrouche N, Arsonnaud S, Kang S. Adapalene gel, 0.1 %, as maintenance therapy for acne vulgaris: a randomized, controlled, investigator-blind follow-up of a recent combination study. Arch Dermatol 2006; 142: 597-602.
72. Alirezai M, George SA, Coutts I, Roseeuw DI, Hachem JP, Kerrouche N, Sidou F, Soto P. Daily treatment with adapalene gel 0.1 % maintains initial improvement of acne vulgaris previously treated with oral lymecycline. Eur J Dermatol 2007; 17: 45-51. (Pubitemid 46383220)
73. Leyden J, Thiboutot DM, Shalita AR, Webster G, Washenik K, Strober BE, Shupack J. Comparison of tazarotene and minocycline maintenance therapies in acne vulgaris: a multicenter, double-blind, randomized, parallel-group study. Arch Dermatol 2006; 142: 605-612. (Pubitemid 43727551)
74. Clucas A, Verschoore M, Sorba V, Poncet M, Baker M, Czernielewski J. Adapalene 0.1 % gel is better tolerated than tretinoin 0.025 % gel in acne patients. J Am Acad Dermatol 1997; 36: S116-S118. (Pubitemid 27265892)
75. Brand B, Gilbert R, Baker MD, Poncet M, Greenspan A, Georgeian K, Soto P. Cumulative irritancy potential of adapalene cream 0.1 % compared with adapalene gel 0.1 % and several tretinoin formulations. Cutis 2003; 72: 455-458. (Pubitemid 38056541)
76. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1 % cream and gel compared with tretinoin microsphere 0.04 % and 0.1 %. Cutis 2005; 75: 238-243. (Pubitemid 40627632)
77. Dosik JS, Homer K, Arsonnaud S. Cumulative irritation potential of adapalene 0.1 % cream and gel compared with tazarotene cream 0.05 % and 0.1 %. Cutis 2005; 75: 289-293. (Pubitemid 40826409)
78. Brand B, Gilbert R, Baker MD, Poncet M, Greenspan A, Georgeian K, Soloff AM. Cumulative irritancy comparison of adapalene gel 0.1 % versus other retinoid products when applied in combination with topical antimicrobial agents. J Am Acad Dermatol 2003; 49: S227-S232. (Pubitemid 37046537)
79. Dosik JS, Gilbert RD, Arsonnaud S. Cumulative irritancy comparison of topical retinoid and antimicrobial combination therapies. Skinmed 2006; 5: 219-223.
80. Laquieze S, Czernielewski J, Rueda MJ. Beneficial effect of a moisturizing cream as adjunctive treatment to oral isotretinoin or topical tretinoin in the management of acne. J Drugs Dermatol 2006; 5: 985-990.
81. Latriano L, Tzimas G, Wong F, Wills RJ. The percutaneous absorption of topically applied tretinoin and its effect on endogenous concentrations of tretinoin and its metabolites after single doses or long-term use. J Am Acad Dermatol 1997; 36: S37-S46. (Pubitemid 27132000)
82. Lipson AH, Collins F, Webster WS. Multiple congenital defects associated with maternal use of topical tretinoin. Lancet 1993; 341: 1352-1353. (Pubitemid 23148136)
83. Navarre-Belhassen C, Blanchet P, Hillaire-Buys D, Sarda P, Blayac JP. Multiple congenital malformations associated with topical tretinoin. Ann Pharmacother 1998; 32: 505-506. (Pubitemid 28166621)
84. Jick SS, Terris BZ, Jick H. First trime-ster topical tretinoin and congenital disorders. Lancet 1993; 341: 1181-1182. (Pubitemid 23137115)
85. Loureiro KD, Kao KK, Jones KL, Alvarado S, Chavez C, Dick L, Felix R, Johnson D, Chambers CD. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A 2005; 136: 117-121. (Pubitemid 40967099)
86. Jensen BK, McGann LA, Kachevsky V, Franz TJ. The negligible systemic availability of retinoids with multiple and excessive topical application of isotretinoin 0.05% gel (Isotrex) in patients with acne vulgaris. J Am Acad Dermatol 1991; 24: 425-428.
87. Cunliffe WJ, Glass D, Goode K, Stables GI, Boorman GC. A double-blind investigation of the potential systemic absorption of isotretinoin, when combined with chemical sunscreens, following topical application to patients with widespread acne of the face and trunk. Acta Derm Venereol 2001; 81: 14-17.
88. Shroot B, Michel S. Pharmacology and chemistry of adapalene. J Am Acad Dermatol 1997; 36: S96-103.
89. Martin B, Meunier C, Montels D, Watts O. Chemical stability of adapalene and tretinoin when combined with benzoyl peroxide in presence and in absence of visible light and ultraviolet radiation. Br J Dermatol 1998; 139 Suppl 52: 8-11. (Pubitemid 28475277)
90. Autret E, Berjot M, Jonville-Bera AP, Aubry MC, Moraine C. Anophthalmia and agenesis of optic chiasma associated with adapalene gel in early pregnancy. Lancet 1997; 350:339. (Pubitemid 27351123)
91. Menter A. Pharmacokinetics and safety of tazarotene. J Am Acad Dermatol 2000; 43: S31-S35.